+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 19Years +
MALE
ID07853209

Evaluating the Efficacy and Safety of 177LuLudotadipep in Men with Metastatic Castration-Resistant Prostate Cancer Compared to Standard Care

Led by FutureChem · Updated on 2026-10-01

114

Participants Needed

8

Research Sites

43 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of 177LuLudotadipep for men with metastatic castration-resistant prostate cancer, a type of advanced prostate cancer that no longer responds to hormone therapy. This phase 3 study compares the investigational drug plus best supportive carestandard of care BSCSoC against BSCSoC alone. The main goal is to measure radiographic progression-free survival rPFS, which tracks the time until cancer worsens or death occurs. Participants receive 177LuLudotadipep intravenously every 8 weeks for up to 4 cycles, with the option for up to 6 cycles based on clinical judgment, alongside their usual cancer care BSCSoC. Those in the control group receive BSCSoC alone and may switch to the investigational drug if their cancer progresses. Before randomization, investigators decide on the most suitable BSCSoC for each participant. During the study, participants undergo regular assessments including imaging scans like CT, MRI, or bone scans to monitor cancer progression. Researchers also evaluate overall survival, duration of response, quality of life through pain and functional questionnaires, and biochemical markers such as PSA levels and enzymes related to cancer activity. The study follows participants for up to 36 months to fully assess these outcomes and monitor safety.

CONDITIONS

Brief Title

A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer

Research Team

C

Chan Soo Park

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here